You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

Oncology Nurse View: Immune Checkpoint Inhibitors in Genitourinary Cancers

  • Authors:

    Sally Rafikh, RN, BSN, OCN; Pam Profusek, RN, MS; Virginia Seery, RN, MSN, ANP-BC

  • CE Released: 6/24/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 6/24/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for oncology nurses.

The goal of this activity is to provide oncology nurses with the latest information on immunotherapy in genitourinary cancers, including strategies for counseling patients and caregivers about immunotherapy.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Efficacy and safety of immune checkpoint inhibitors in advanced renal cell carcinoma (RCC) and bladder cancer
  • Have greater competence related to
    • Mitigating the adverse events related to treatments for advanced RCC and bladder cancer
    • Counseling patients regarding differentiation of adverse events related to immunotherapy vs traditional cancer therapies


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Sally Rafikh, RN, BSN, OCN

    Clinical Nurse
    GU Medical Oncology
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Disclosure: Sally Rafikh, RN, BSN, OCN, has disclosed no relevant financial relationships.

    Ms Rafikh does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Rafikh does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Pam Profusek, RN, MS

    GU Research Nurse Coordinator
    Taussig Cancer Center
    Cleveland Clinic
    Cleveland, Ohio

    Disclosures

    Disclosure: Pam Profusek, RN, MS, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Genentech, Inc.

    Ms Profusek does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Profusek does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Virginia Seery, RN, MSN, ANP-BC

    Nurse Practitioner
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts

    Disclosures

    Disclosure: Virginia Seery, RN, MSN, ANP-BC, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Array BioPharma

    Ms Seery does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Seery does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Davecia R. Cameron, MS

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CE Reviewer / Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

Oncology Nurse View: Immune Checkpoint Inhibitors in Genitourinary Cancers

Authors: Sally Rafikh, RN, BSN, OCN; Pam Profusek, RN, MS; Virginia Seery, RN, MSN, ANP-BCFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CE Released: 6/24/2018

Valid for credit through: 6/24/2019

processing....

Educational Impact Challenge

The goal of this activity is to provide oncology nurses with the latest information on immunotherapy in genitourinary cancers, including strategies for counseling patients and caregivers about immunotherapy.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print